


Kadcyla 160mg Injection
Written By Dr. Sakshi Jain, MS, BDS,
Reviewed By Dr. Mekhala Chandra, MD, MBBS,
Last updated on 19 Nov 2026 | 01:01 AM (IST)
Save more with additional offers







General Information
Contains
Marketer
Storage



Product introduction
Kadcyla 160mg Injection is given as a drip into a vein (intravenous infusion) by a doctor or nurse in a hospital or clinic. It is usually given once every three weeks. Your doctor will decide the dose based on your body weight, condition, and response to treatment. The duration of treatment depends on the type and stage of breast cancer. Do not miss or stop your treatment without consulting your doctor.
The most common side effects of Kadcyla 160mg Injection include tiredness, nausea, headache, muscle or joint pain, bleeding, and a decrease in platelet count. A low platelet count may increase the risk of bleeding or bruising. This medicine may also affect the liver, heart, and nerves. Your doctor will regularly monitor your blood cell counts, liver function, and heart function during treatment. Inform your doctor immediately if you experience unusual bleeding, yellowing of the skin or eyes, breathlessness, or swelling of the feet.
Before starting Kadcyla 160mg Injection, inform your doctor if you have heart, liver, or kidney problems, breathing difficulties, or a history of bleeding problems. Tell your doctor about all the medicines you are taking. This medicine may harm an unborn baby and should not be used during pregnancy. Women who can become pregnant should use effective contraception during treatment and for 7 months after the last dose. Men with female partners who can become pregnant should use effective contraception during treatment and for 4 months after the last dose. Breastfeeding should be avoided during treatment and for 7 months after the last dose.
There is a Patient Support Program/Patient Assistance Program available in India for this medicine, being managed by Tata 1mg. Please contact your prescribing doctor to know more about the same. You may also call on (1800-102-1618) for more details.
Uses of Kadcyla Injection
- Breast cancer
- Metastatic breast cancer
Benefits of Kadcyla Injection
Kadcyla 160mg Injection is used to treat HER2-positive early breast cancer when some cancer remains after chemotherapy and HER2-targeted treatment given before surgery. It helps destroy remaining cancer cells and reduces the risk of cancer returning. This medicine works by targeting cancer cells that have a protein called HER2 on their surface. Your doctor will monitor your response to treatment and manage any side effects that may occur.
Kadcyla 160mg Injection is used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer). It is prescribed to patients who have previously received certain cancer treatments, including trastuzumab and taxane-based chemotherapy. This medicine targets HER2-positive cancer cells and helps slow down their growth and spread. It may help shrink tumours, control the disease, and improve survival in suitable patients.
Side effects of Kadcyla Injection
- Abdominal pain
- Nausea
- Vomiting
- Musculoskeletal (bone, muscle or joint) pain
- Decreased red blood cell count
- Headache
- Respiratory tract infection
- Decreased white blood cell count (lymphocytes)
- Injection site redness
How to use Kadcyla Injection
How Kadcyla Injection works
Quick tips
- Kadcyla 160mg Injection is given via a drip into a vein (intravenous infusion) under the supervision of a doctor.
- Your doctor will check your liver function before starting treatment and before each dose of Kadcyla 160mg Injection. Inform your doctor immediately if you notice yellowing of the skin or eyes, dark urine, severe tiredness, or pain in the upper right side of your stomach.
- Women who can become pregnant should use effective contraception during treatment with Kadcyla 160mg Injection and for 7 months after the last dose. Men with female partners who can become pregnant should use effective contraception during treatment and for 4 months after the last dose.
- Inform your doctor immediately if you experience breathlessness, swelling of the feet, unusual bleeding, or easy bruising.
- Kadcyla 160mg Injection may rarely cause serious lung problems. Inform your doctor immediately if you develop new or worsening cough, difficulty breathing, or fever.
Safety advice

Alcohol

Pregnancy

Breast feeding

Driving

Kidney

Liver
Frequently asked questions
Fact Box
Chemical Class
Habit Forming
Therapeutic Class
Action Class
Related lab tests
References
- Kadcyla. Ado-trastuzumab emtansine. [Accessed 26 Mar. 2019] (online) Available from:
- Ado-trastuzumab emtansine. South San Francisco, CA: Genentech, Inc.; [Accessed 26 Mar. 2019] (online) Available from:
- Trastuzumab emtansine. Emil-Barell-Strasse: Roche Registration GmbH; 2013 [revised 17 Sep. 2018]. [Accessed 26 Mar. 2019] (online) Available from:




User feedback
Want to know more
We provide you with authentic, trustworthy and relevant informationHave issue with the content
Disclaimer
Marketer details
Address: 1503, 15th Floor, ‘The Capital’, Plot no. C-70, Behind ICICI Bank, BKC, Bandra (E) , Mumbai 400051
Vendor Details
Lab tests offered by us
- CBC (Complete Blood Count)
- FBS (Fasting Blood Sugar)
- Thyroid Profile Total (T3, T4 & TSH)
- HbA1c (Glycosylated Hemoglobin)
- PPBS (Postprandial Blood Sugar)
- Lipid Profile
- Vitamin D (25-Hydroxy)
- Urine R/M (Urine Routine & Microscopy)
- Coronavirus Covid -19 test- RT PCR
- LFT (Liver Function Test)
- KFT (Kidney Function Test)
- TSH (Thyroid Stimulating Hormone) Ultrasensitive
- ESR (Erythrocyte Sedimentation Rate)
- Uric Acid, Serum
- Vitamin B12
- CRP (C-Reactive Protein), Quantitative
- Urine C/S (Urine Culture and Sensitivity)
- Serum Electrolytes
- Serum Calcium
- Serum Creatinine
- Diabetes Screening (HbA1C & Fasting Sugar)
- KFT with Electrolytes (Kidney Function Test with Electrolytes)
- Cholesterol - Total
- Hb (Hemoglobin)
- Complete Hemogram (CBC & ESR)
















